Is There a Place for Temozolomide plus Nivolumab among Neuroendocrine Neoplasms?

Maria A Velez; Edward B Garon

doi:10.1158/1078-0432.CCR-22-3229

Is There a Place for Temozolomide plus Nivolumab among Neuroendocrine Neoplasms?

Clin Cancer Res. 2023 Feb 16;29(4):691-693. doi: 10.1158/1078-0432.CCR-22-3229.

Authors

Maria A Velez¹, Edward B Garon^{1

2}

Affiliations

¹ Department of Medicine, Division of Hematology/Oncology, University of California, Los Angeles, Los Angeles, California.
² University of California Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, California.

PMID: 36520037
DOI: 10.1158/1078-0432.CCR-22-3229

Abstract

Immune checkpoint inhibitors have revolutionized the treatment of multiple solid malignancies, but their role in the treatment of neuroendocrine neoplasms (NEN) is unclear. The accompanying article reports on a study combining the programmed cell death (PD-1) inhibitor nivolumab with the alkylating agent temozolomide in patients with advanced NENs. See related article by Owen et al., p. 731.

Publication types

Editorial

MeSH terms

Humans
Neuroendocrine Tumors* / pathology
Nivolumab* / therapeutic use
Temozolomide / therapeutic use

Substances

Nivolumab
Temozolomide